Attenuation of behavioral abnormalities in autoimmune mice by chronic soluble interferon-gamma receptor treatment.
Attenuation of behavioral abnormalities in autoimmune mice by chronic soluble interferon-gamma receptor treatment.
复制标题
通过长期可溶性干扰素-γ受体治疗减轻自身免疫小鼠的行为异常。
DOI：
10.1006/brbi.1998.0522
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
Crnic,LS
中科院分区：
文献类型：
--
作者：
Schrott,LM;Crnic,LS
NZB × NZW F1 hybrid (B/W) mice develop altered behavior in the elevated plus maze and novel object tasks between 6 and 12 weeks of age in parallel with lupus-like autoimmune disease. To confirm the relationship between disease progression and development of behavioral abnormalities, B/W and nonautoimmune NZW mice received chronic treatment with a soluble IFNγ receptor (sIFNγR), a treatment known to retard autoimmune disease progression, or vehicle, beginning at 6 weeks of age. After 6 weeks of treatment, elevated plus maze and novel object testing revealed that although sIFNγR treated B/W mice still differed from NZW mice, chronic sIFNγR treatment significantly retarded the development of behavioral abnormalities in the B/W mice, while the NZW mice were not affected by this treatment. sIFNγR treated B/W mice were more active in both the plus maze and novel object tasks, and displayed less plus maze anxiety behavior and more exploratory activity in the novel object task compared to vehicle treated B/W mice. To clarify the role of acute action of the sIFNγR on the elevated IFNγ levels of B/W mice, a second experiment examined the effects of a single injection of sIFNγR on B/W and NZW mice. Unlike chronic treatment, acute treatment with the same dose of sIFNγR did not affect plus maze or novel object behavior in 12-week-old mice. These results add to the growing evidence that lupus-associated behavioral abnormalities are a direct effect of the autoimmune disease.
